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Background and Aims. Deoxyribonuclease I (DNaseI) is an endonuclease that facilitates chromatin breakdown and promotes
susceptibility to autoimmune disorders. The aim of current study was to investigate serum DNase I activity in patients with
inﬂammatory bowel diseases (IBD). Patients and Methods. A cohort of 110 IBD patients was evaluated, aged 35 ± 12 years, 77
with Crohn’s disease (CD) and 33 with ulcerative colitis (UC). 50SLE patients and 50 healthy blood donors were examined as
control groups. Results. DNase I activity in IBD patients was signiﬁcantly lower than in healthy individuals, but higher than in
SLE patients (P<. 0001). Patients with UC showed higher DNase I activity than CD patients, P = .21. DNase I activity in female
patients with IBD was signiﬁcantly lower than in males, P = .024; however, no diﬀerences in DNase I activity were found in
relation to gender in healthy individuals. DNaseI activity has showna strongnegative correlation withthe serum concentrationof
anti-nucleosomal antibodies in the autoimmune (SLE + IBD) cohort, as well as in the separate IBD cohort. Conclusions. Reduced
serum DNase I activity probably has pathogenetic consequences in IBD. Induction of autoantibodies towards nucleosomes could
be a reﬂection of impaired DNase I activity.
1.Introduction
Autoimmunediseases aﬀect more than 5% of the population
in developed countries and are an important cause of
morbidity and mortality [1]. They are often of multi-
factorial etiology and are characterized by the presence
of autoantibodies and/or autoreactive lymphocytes. Dif-
ferent mechanisms for the pathogenesis of autoimmune
diseases have been suggested, including deregulation of
the immune system which leads to loss of self-tolerance;
molecular mimicry mechanisms; idiotypical cross-reactions;
defective apoptosis of antigen-presenting cells; aberrant B-
cellreceptor-mediatedfeedback;defectiveremoval ofcellular
debris after cell death.
The last mentioned removal of cellular debris during cell
death is important for preserving autoimmunity to cellular,
especially nuclear, antigens. The degradation of DNA into
nucleosomal units during cell death is mediated by enzymes
called deoxyribonucleases (DNases) [2]. The two main types
of DNase found in humans are known as DNase I and2 Autoimmune Diseases
DNase II. DNase I is an endonuclease that participates in
degradation of DNA that was not eﬃciently engulfed [3]. It
is secreted into most body ﬂuids by a variety of endocrine
and exocrine glands [3–5], and its physiological functions
are supposed to be degrading the DNA of dietary substances
within the intestinal tract (to supply an organism with
oligonucleotides) and suppressing anti-DNA autoimmunity
by degrading chromatin released from dying cells [6, 7].
Deﬁciency in DNase I enzyme, and the resulting diﬃculty
of removing DNA from nuclear antigens, promotes suscep-
tibility to autoimmune disorders [7]. Failure of apoptosis
leads to the development of a lupus-like syndrome [8].
DNase I deﬁciency was also found in patients with systemic
lupus erythematosus (SLE), correlating with high titers of
antibodies against nucleosomal antigens [9–11]. It has been
shown that SLE patientswith a single nucleotidemutation in
t h eg e n ef o rD N a s eIe x h i b i t1 0 – 4 0 %o ft h eD N a s eIa c t i v i t y
that healthy individuals normally display [11].
We have hypothesized that altered DNase I activity
could be related to the immunopathogenesis of autoim-
mune disorders that are distinct from SLE. We focused, in
particular, on inﬂammatory bowel diseases (IBD). IBD, of
which there are two main types—Crohn’s disease (CD) and
ulcerative colitis(UC)—may aﬀect between 20,000 to 40,000
people in the Czech Republic [12]. The pathogenesis of
IBD is only partially understood yet. Various environmental
and host factors, some genetic and immunological, are
involved. During the last decade, several new pathways have
been suggested for the immunopathogenesis of IBD. It is
proposed, for example, that in the antigen-rich environment
of the gut, lymphocyte activation and expansion must be
highlycontrolled; thisisensured byT-lymphocyte apoptosis.
In IBD patients, Fas/FasL activation has been proven to
diminish apoptosis [13, 14], and defective apoptosis seems
to be a relevant pathogenetic mechanism in chronic IBD.
The aims of our study were to (i) investigate serum
DNase I activity in patients with CD and UC; (ii) compare
values from IBD patients with SLE patients and healthy
individuals; (iii) investigate a possible link between serum
DNase I activity and serum levels of antibodies against
nuclear autoantigens in IBD patients.
2.MaterialandMethods
2.1. Patients. We evaluated a cohort of 110 IBD patients, in
whom diagnosis of IBD was established in accordance with
standardized sets of clinical, endoscopic, and/or radiological
and histopathological criteria [15]. Calculated mean age in
the cohort was 35 ± 12 years. Seventy-seven patients were
diagnosed with CD, and 33 patients had UC. Sixty-nine
patients were women and 41 were men. All of the IBD
patients examined had severely active disease and have had
an inadequate response to previous conventional therapy.
Two control age-matched groups were examined: 50 SLE
patients (40 females, 10 males) and 50 healthy blood donors
(equal numbers of women and men).
Blood samples were drawn before the initiation of
biological treatment by inﬂiximab or adalimumab. In 45
randomly selected IBD patients, an additional blood sample
was taken after the induction phase of treatment, that is, six
weeks later. All SLE patients fulﬁlled the diagnostic criteria
of the American College of Rheumatology [16]. Nine had
an active disease, in 41 clinical remission was achieved.
Forty-six (92%) of SLE patients had proven lupus nephritis.
Samples from healthy blood donors were taken before blood
donation.
2.2. Ethical Aspects. The study was approved by the Institu-
tionalEthicalCommittee.Thepurposeandproceduresofthe
study were explained to participants, who signed informed
consent forms.
2.3. Laboratory Examinations. Serum was used for DNase
I activity and serum IgG antinucleosomal antibodies mea-
surement. In patients with IBD who were repeatedly exam-
ined during the anti-inﬂammatory biological treatment, C-
reactive protein (CRP) was measured as an acute phase
reactant, to assess the eﬀectiveness of treatment. Blood
samples were taken from the cubital vein and centrifuged for
10 minutes at ambient temperature and 1300g. Separated
serum aliquots were frozen at −80◦C. The frozen serum
samples werethawedonceonicebeforeanalysis. Alldetermi-
nations were done in two replicates. Samples were measured
together to preclude the possibility of errors derived from
interassay variability.
Serum DNase I activity was determined by a novel
validated standardized enzyme-linked immunosorbent assay
(DNase Activity, Orgentec, Germany). In short, samples
were added to a DNA-coated 96 well microplate and
incubated for 1 hour at 37◦C. Horseradish peroxidase (HRP)
conjugated anti-DNase I antibodies colorare added and
incubated for 15 minutes at room temperature to react with
the remaining uncleaved DNA. The intensity of the color
developedduringtheenzymaticreaction(hydrolysisofHRP-
substrate, 3,3 ,5,5 -tetramethyl-benzidine (TMB) and acid
addition) was measured photometrically at 450nm using a
MRXII (Dynatech, UK) photometer and analyzed it using
the software Revelation (Dynatech, UK). A standard series,
as well as positive and negative controls, were included in
the kit. The amount of color was inversely proportional to
the amount of DNase activity. 75% was set as a cutoﬀ value
for DNase I activity (which corresponds to the 25% activity
reduction).
Antinucleosomal antibodies in the IgG isotype were
detected using a validated, standardized, enzyme-linked
immunosorbent assay (Anti-Nucleosome, Orgentec, Ger-
many). Values below 20U/mL were considered negative
according to manufacturer’s recommendations. CRP was
measured using nephelometry (BNII, Siemens Healthcare
Diagnostics, Germany). The reference range 0–5mg/L was
used per the manufacturer’s recommendations.
2.4. Statistical Analysis. Prior to running experiments,
required sample size was calculated by Statistica Power
Analysis (StatSoft Inc., USA).Autoimmune Diseases 3
Kruskal-Wallis test:
KW-H (3; 208) = 112.6169; P<. 0001
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Figure 1: DNase I activity in diﬀerent groups of patients. DNase
I: deoxyribonuclease I; SLE: systemic lupus erythematosus; UC:
ulcerative colitis; CD: Crohn’s disease; C: healthy controls. The
boxplot represents the lower and upper quartiles, the horizontal
line represents the median, and the whiskers represent the sample
minimum and maximum.
Statistical analysis was performed using the software
Statistica CZ 7.0 (StatSoft Inc., USA). Diﬀerent groups were
compared using the Mann-Whitney U-test or a two-sided
Kruskal-Wallis nonparametric test. The Spearman rank test
was used to identify correlations between variables. The
threshold for signiﬁcance was set at P<. 05.
3.Results
3.1. DNase I Activityin IBD. DNase I activity in IBD patients
(63 ±19%)wassigniﬁcantly lowerthanthatofhealthyblood
donors (92 ± 11%), but higher than that of SLE patients
(36 ± 19%), P<. 0001. Patients with UC showed higher
DNase I activity (74 ± 19%) than CD patients (61 ± 18%);
see Figure 1. Only 21 of 110 IBD patients (19%) had DNase I
activity above the reference cutoﬀ value of 75%.
3.2. DNase I Activity and Gender. DNase I activity in female
patients with IBD (52 ± 21%) was signiﬁcantly lower than
in male patients (69 ± 21%), P = .024. Similarly, in SLE
patients, female DNase I activity (31 ± 14%) was lower than
male DNase I activity (40 ± 21%), P = .032. However, in
healthy individuals, no diﬀerences in DNase I activity were
found in relation to gender; see Figure 2.
3.3. DNase I Activity and Inﬂammation. DNase I activity did
not oscillate during anti-inﬂammatory biological treatment
with inﬂiximab oradalimumab. In addition, DNaseI activity
did not correlate with serum CRP (r = 0.128, P = .654).
Each patient treated had stable DNase I activity during the
entire induction phase of biological therapy (see Table 1).
3.4. DNase I Activity and Antinucleosomal Antibodies. DNase
I activity has shown a strong negative correlation with
the serum concentration of antinucleosomal antibodies in
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Figure 2: DNase I activity and gender. DNase I: deoxyribonuclease
I; SLE: systemic lupus erythematosus; IBD: inﬂammatory bowel
diseases; CTRL: healthy controls.
Table 1: Dynamics of DNase I activity and serum CRP concen-
tration in IBD patients during the induction phase of biological
treatment (n = 45).
W0 W6 P-value∗
DNase I activity (%) 67 (54,75) 68 (51,78 ) .724, NS
CRP (g/L) 31 (24, 39) 5 (1, 9) <.001
Data are expressed as medians (interquartile range).
W0: week 0 of biological treatment; W6: week 6 of biological treatment;
DNase I: deoxyribonuclease I; CRP: C-reactive protein; NS: nonsigniﬁcant
∗Mann-Whitney U-test.
the autoimmune (SLE + IBD) cohort, as well as in the
separate IBD cohort (see Figures 3(a) and 3(b)). However it
must be emphasized that concentrations of antinucleosomal
autoantibodies in IBD patients did not reach as high values
as SLE patients (P = .001).
4.Discussion
To our knowledge, this is the ﬁrst report on serum DNase
I activity in IBD patients. We have found that DNase I
activity is signiﬁcantly decreased in IBD patients, though the
reduction was not as great as in SLE patients. CD patients
had lowervaluesthan UCpatients, while female patientshad
lower values than male patients. DNase I activity was not
aﬀected by anti-inﬂammatory processes during biological
treatment of IBD. Similarly to SLE, DNase I activity in
IBD patients has shown a negative correlation with the
occurrence of antinucleosomal autoantibodies.
A deﬁciency in DNase I enzyme, as well as the resulting
diﬃculty ofremoving DNAfrom nuclearantigens, promotes
susceptibility to autoimmune disorders. DNase I activity is
often abnormally low in SLE patients. Low DNase I activity4 Autoimmune Diseases
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Figure 3: Correlation of DNase I activity with the level of antinucleosomal antibodies. DNase I: deoxyribonuclease I; Ab: antibodies.
has already been proven in diﬀerent systemic and organ
speciﬁc autoimmune diseases: SLE [17], Sj¨ ogren’s disease
[18] and thyroid autoimmunity [19].
The immunopathogenesis of IBD is not clear yet. Our
results suggest that imbalance of the events that control
cleanup of the cell debris may contribute to the pathogenesis
of IBD. One might expect lower DNase I activity in IBD
patients with active local and/or systemic inﬂammation.
However, we did not ﬁnd a signiﬁcant diﬀerence between
the DNase I activity of our IBD patient groups before and
after the induction phase of anti-inﬂammatory biological
treatment. This indicates that reduced DNase I activity could
be inherent, independent of the inﬂammatory processes and
cascades. The true reason for reduced endonuclease activity
has not been determined. A genetic mutation of the DNASEI
gene has been reported in SLE patients [20]. To date, no
reports about this mutation in IBD patients were published.
We are not able to claim if subjects with reduced DNase
I activity may be more susceptbile to IBD compared with
the normal activity levels harboring ones. However, genetic
heterogeneityin the DNaseI geneaﬀecting its in vivo activity
has been less demonstrated as yet.
Interestingly, CD patients from our IBD cohort have
shownDNaseIactivity thatislowerthanthatofUCpatients.
This could be explained by the diﬀerent etiopathogenesis of
these two (CD and UC) inﬂammatory entities.
Our results did not validate Martinez-Valle’s ﬁnding that
men have lower DNase I activity than women [11]. On the
contrary, in our IBD and SLE cohorts, DNase I activity was
lower in female patients. We suggest that defective cellular
waste disposal in females with lower DNase I activity leads to
the release of nuclear components (and prolonged exposure
to them) and that lower DNase I activity in women could be
an additional feature of sexual dimorphism of the immune
system. On the other hand, DNase I activity in healthy
females did not diﬀer from the healthy males. This could
reﬂect genetic predisposition in aﬀected females.
As is known, DNA itself is not immunogenic, and
only when bound to proteins (i.e., histones) it can induce
immune response [21–23]. Therefore, DNA-histone com-
plexes (nucleosomes) are proposed to be the genuine
autoantigens in autoimmune diseases. Sallai et al. ﬁrstly
described a negative correlation between DNase I activity
and antinucleosomal antibodies in people aﬄicted with SLE
[21]. In support of an association between antinucleosomal
antibody production and DNase I activity, we found that
IBD patients with positive antinucleosomal antibodies had
signiﬁcantly lower DNase I activity than their counterparts
withlowconcentrationsoftheseautoantibodies. Thebalance
between levels of circulating nucleosomes, DNase I activity
and the formation of antinucleosomal autoantibodies is a
dynamic process and, therefore, obtaining clear proof of the
association between these three would require simultaneous
investigation ofDNaseIactivityandcirculatingnucleosomes
and antinucleosomal antibody levels.
Our study has some limitations. The most important
limitation concerns the constitution of our IBD cohort.
All of the 110 IBD patients had active severe disease,
with the necessity of the biological treatment. Therefore,
our cohort does not represent a typical IBD group of
patients, but their most serious fraction. Secondly, some
of our IBD patients have shown positive antinucleosomal
antibodies, which are not common in IBD. We suggest that
in such severe inﬂammation and coincidental low DNase
I activity, apoptotic cells are not cleared suﬃciently and
they deviate from a well-organized apoptotic process into
secondary necrosis. This could result in an altered self-form
of chromatin unmasking, which is able to provide the same
danger signal as infectious nonself structures and could be a
targetstructureforinducedantinucleosomal autoantibodies.
In summary, our results indicate that reduced serum
DNase I activity is common in severe IBD and that decreased
DNase I activity could be one of the pathogenetic factors in
IBD development.Autoimmune Diseases 5
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